No Known Direct Interactions
Vascepa (icosapent ethyl), a purified EPA omega-3 fatty acid used to lower triglycerides, has no documented pharmacokinetic or pharmacodynamic interactions with vitamin D supplements or deficiency states. Clinical trials, prescribing information, and drug interaction databases like Drugs.com and Lexicomp report no alerts for this combination.[1][2]
How Vascepa and Vitamin D Work
Vascepa reduces triglyceride synthesis in the liver and enhances clearance without affecting LDL cholesterol significantly. Vitamin D regulates calcium absorption, bone health, and inflammation via receptor binding. Their mechanisms do not overlap—Vascepa targets lipid metabolism, while vitamin D influences endocrine and immune pathways—reducing interaction risk.[3][4]
Potential Indirect Effects Patients Ask About
- Bleeding risk: Vascepa mildly increases bleeding time in high doses, but vitamin D does not affect coagulation. No amplified risk together, unlike with anticoagulants.[1]
- Bone health and lipids: Vitamin D deficiency links to dyslipidemia, but Vascepa does not alter vitamin D levels or metabolism. Supplementation may indirectly support cardiovascular health without interfering.[5]
- Inflammation: Both have anti-inflammatory effects (Vascepa via resolvins, vitamin D via cytokines), potentially additive but not antagonistic.[3]
What Happens If You Take Them Together?
Patients commonly combine them without issues in REDUCE-IT trial data and real-world use. No dose adjustments needed. Monitor triglycerides and vitamin D levels routinely if prescribed for deficiency.[1][6]
When to Check with a Doctor
Consult for personalized advice if you have liver disease, take statins, or high-dose vitamin D (>4,000 IU daily), as unrelated factors could influence monitoring. No routine interaction testing required.[2]
[1]: Vascepa Prescribing Information
[2]: Drugs.com - Vascepa Interactions
[3]: PubMed - Icosapent Ethyl Mechanism
[4]: NIH - Vitamin D Fact Sheet
[5]: Journal of Clinical Endocrinology - Vitamin D and Lipids
[6]: NEJM - REDUCE-IT Trial